FG Moves to Cut Nigeria’s Dependence on Imported Medical Tests as Diagnostics Become Health-Security Priority
By Iroyin Yoruba Television News Desk
The Federal Government has declared medical diagnostics a strategic national asset and called for a stronger domestic industry capable of producing diagnostic products, supporting disease surveillance and reducing Nigeria's dependence on imported laboratory materials.
The Minister of State for Health and Social Welfare, Dr Iziaq Salako, made the declaration in Abuja on September 16, 2026, while opening the 28th Scientific Conference and Annual General Meeting of the Guild of Medical Laboratory Directors.
Represented by the Director and Head of the Medical Laboratory Services Division in the Federal Ministry of Health and Social Welfare, Dr Emeka Elom, Salako said accurate and timely diagnosis was essential not only to individual patient care but also to disease surveillance and public-health decision-making.
He said Nigeria's pursuit of what he described as diagnostic sovereignty would require more than establishing factories that manufacture test kits.
According to the minister, the country also needs technology transfer, research and innovation, effective regulation, sustainable procurement and strategic partnerships if locally produced diagnostic products are to become reliable, affordable and widely available.
The announcement places laboratory diagnostics inside the wider conversation about Nigeria's health security and local healthcare manufacturing.
It also creates a new policy question: how can Nigeria develop domestic capacity without compromising the accuracy, safety and international standards required of medical tests?
That question is particularly important because diagnostic products are not ordinary consumer goods. A defective or unreliable test can influence a clinical decision, delay treatment or affect the interpretation of an outbreak.
The government's latest position therefore involves both industrial policy and patient safety.
Why diagnostics are being treated as a strategic national asset
Medical diagnosis is one of the first stages through which healthcare providers determine what is happening inside a patient's body.
Blood tests, urine tests, microbiological examinations, imaging-related diagnostics, molecular tests and other laboratory procedures can provide evidence needed to identify disease, monitor treatment or investigate unusual symptoms.
The information generated by laboratories also extends beyond individual patients.
Public-health authorities use laboratory results to monitor infectious diseases, investigate outbreaks and determine whether a suspected health threat is spreading.
This means that a country's diagnostic capacity influences both routine healthcare and emergency preparedness.
Salako said accurate and timely diagnosis was critical to healthcare delivery, disease surveillance and public-health decisions.
The Federal Government's description of diagnostics as a strategic national asset therefore reflects their role across several parts of the health system.
A hospital depends on diagnostic information to support clinical decisions.
A disease-control agency depends on laboratory evidence to identify pathogens.
Researchers depend on reliable tests to generate scientific evidence.
Regulators depend on testing and quality-control systems to protect the public.
Health planners depend on disease information to determine where resources should be directed.
A weakness in one part of that chain can affect the others.
The import-dependence problem
Nigeria's medical laboratory system relies on a wide range of products, including reagents, consumables, equipment and other materials used in testing.
The Guild of Medical Laboratory Directors has called for Nigeria to reduce what it describes as heavy dependence on imported diagnostic reagents, consumables and equipment.
Guild President Dr Samuel Fele argued that excessive dependence on imported products limits opportunities for the development of a competitive domestic diagnostic industry.
The government's response is not to suggest that every diagnostic product must immediately be manufactured domestically.
Instead, the September 16 announcement points toward building the capabilities required to produce more products locally while maintaining appropriate standards.
That distinction is important.
A country can have a local manufacturing facility and still depend on imported raw materials, specialised components, machinery, technical expertise or intellectual property.
For that reason, the minister said technology transfer, research and innovation must accompany local production.
The broader goal is to develop an ecosystem rather than simply establish isolated factories.
What diagnostic sovereignty actually involves
The phrase "diagnostic sovereignty" can be misunderstood if it is reduced to the question of whether a country manufactures test kits.
A recent academic analysis of diagnostic sovereignty in Africa describes it more broadly as the capacity of health systems to sustainably produce, interpret and govern microbiological evidence for clinical care and public-health surveillance.
The researchers identify technical capacity, institutional capacity and data governance as interconnected elements of that capability.
That means Nigeria's current policy discussion has several dimensions.
The first is manufacturing.
The second is the laboratory workforce capable of using diagnostic technologies correctly.
The third is regulatory capacity.
The fourth is procurement.
The fifth is maintenance and supply-chain reliability.
The sixth is research and innovation.
The seventh is the ability to generate, store and use diagnostic information appropriately.
A country that manufactures a test but lacks laboratories capable of using it properly has not achieved full diagnostic independence.
Likewise, a country that owns laboratories but cannot reliably obtain essential reagents remains vulnerable to external supply disruptions.
Why quality cannot be sacrificed for local production
One of the central challenges facing the government's proposal is quality assurance.
Medical tests have to meet appropriate technical and clinical standards.
A locally manufactured diagnostic product that performs poorly could create new problems rather than solve existing ones.
That is why the September 16 discussion repeatedly linked local manufacturing with regulation and quality assurance.
Fele of the Guild of Medical Laboratory Directors also stressed that increased local production must be accompanied by quality assurance, regulatory oversight and recognised standards.
This creates a two-part requirement for manufacturers.
They need to produce competitively.
They also need to demonstrate that their products work consistently.
For regulators, that means evaluating products before and after they enter the market.
For laboratories, it means following appropriate procedures and quality-control systems.
For government procurement agencies, it means avoiding a system in which the cheapest product automatically becomes the preferred product regardless of performance.
The objective is therefore not simply to replace an imported product with a Nigerian-made product.
The objective is to produce or procure a product that is safe, reliable, effective and economically sustainable.
The regulator's role in the diagnostic ecosystem
Nigeria already has a statutory institution with responsibilities covering parts of the medical laboratory system.
The Medical Laboratory Science Council of Nigeria was established under Act 11 of 2003.
Its functions include regulating the practice of medical laboratory science, setting professional standards, accrediting training institutions, maintaining registers of practitioners and regulating the production, importation, sale and stocking of diagnostic laboratory reagents and chemicals. It also inspects, regulates and accredits medical laboratories.
Those responsibilities become particularly important if domestic diagnostic manufacturing expands.
More manufacturers mean more products that require oversight.
More laboratories mean more facilities requiring accreditation.
More technology can also mean more specialised training requirements.
The regulatory system therefore has to develop alongside the industry.
The MLSCN has also been moving services online through its MLSCNHub platform, which provides services covering practitioner licensing, training institutions, laboratories, continuing professional development and related administrative processes.
Digital regulation can potentially make some processes more transparent and easier to track, although the effectiveness of any regulatory system ultimately depends on enforcement and institutional capacity.
Research is central to the government's proposal
The Federal Government has specifically identified research and innovation as part of the path toward diagnostic sovereignty.
This is important because diagnostic technologies are constantly changing.
Traditional laboratory tests continue to be important, but molecular diagnostics, genomic methods, automation and artificial intelligence are increasingly influencing how diseases are detected and analysed.
If Nigeria's domestic industry is limited to assembling existing products without developing its own research capability, its technological dependence may remain.
Research institutions and universities can contribute by developing new assays, adapting technologies to Nigerian disease patterns and testing locally relevant diagnostic approaches.
Private companies can contribute capital, manufacturing expertise and market knowledge.
Government agencies can provide regulatory frameworks and procurement mechanisms.
The challenge is connecting these institutions so that research findings can move from laboratories into products and ultimately into healthcare facilities.
Technology transfer is more than importing equipment
Technology transfer is another part of the government's proposal.
A company can import a sophisticated diagnostic machine and install it in Nigeria without creating significant domestic technological capacity.
True technology transfer can involve training Nigerian engineers and scientists, establishing local maintenance capability, sharing manufacturing processes and building local expertise around product development.
This distinction matters because equipment eventually requires servicing.
Reagents require supply chains.
Software may need updating.
Machines can become obsolete.
If every technical problem requires an overseas engineer or imported replacement component, a facility may remain vulnerable despite having modern equipment.
Technology transfer can reduce that vulnerability by increasing the number of technical functions that can be performed domestically.
Sustainable procurement could determine whether local factories survive
One of the strongest points raised by the minister was the need for sustainable procurement.
Manufacturers can establish production facilities, but they need a dependable market.
If government hospitals and public laboratories continue to purchase almost entirely from foreign suppliers, local manufacturers may struggle to achieve the production volumes necessary to compete.
On the other hand, simply directing public institutions to buy local products without appropriate quality controls could create a different problem.
Sustainable procurement therefore has to balance several factors.
Quality matters.
Reliability matters.
Price matters.
Supply continuity matters.
Technical support matters.
Local economic value also matters.
Government procurement policies can potentially create a predictable market for qualified Nigerian manufacturers while still requiring products to meet established standards.
This is one reason the current policy discussion is broader than manufacturing alone.
The African market could be larger than Nigeria's domestic market
The Guild of Medical Laboratory Directors has also pointed to the wider African diagnostics market as an opportunity for Nigerian manufacturers.
Nigeria has one of the continent's largest populations and a large healthcare market.
If domestic manufacturers can meet appropriate quality standards and achieve competitive production costs, they could potentially supply other African markets.
That possibility changes the economic calculation.
A factory producing only for a limited domestic market may struggle to achieve economies of scale.
A manufacturer capable of serving several African countries could potentially produce at higher volumes.
However, exporting medical diagnostic products introduces additional regulatory requirements.
Different countries may have different registration processes, quality requirements and procurement systems.
Therefore, the development of an export-oriented Nigerian diagnostics industry would require not only manufacturing capacity but also regulatory competence and internationally recognised quality systems.
The African diagnostics opportunity
The Guild's argument comes against a background of expanding demand for diagnostic services across Africa.
The September conference discussions identified the African diagnostics market as an opportunity for Nigerian manufacturers, while stressing that domestic production must remain connected to quality assurance and standards.
A larger regional market could also encourage investment in specialised manufacturing.
Instead of producing only basic consumables, companies could gradually move into more advanced areas.
That could include molecular diagnostics, specialised reagents, laboratory automation components and other technologies.
But that progression would depend on research investment, skilled personnel, financing and stable regulation.
Why disease surveillance depends on laboratories
The health-security argument becomes especially clear during infectious-disease outbreaks.
When unusual illness appears in a community, health authorities need to know what is causing it.
Symptoms alone may not provide enough information to distinguish between different diseases.
Laboratory testing can provide evidence that helps authorities determine whether a suspected outbreak is occurring.
The result can influence how health agencies respond.
This makes laboratory capacity part of national preparedness.
The academic literature on diagnostic capacity and antimicrobial resistance makes the same point from another angle.
Researchers have argued that antimicrobial resistance cannot be effectively controlled where microbiological evidence is weak because health systems need laboratory information to identify resistant organisms and guide appropriate treatment and surveillance.
The issue therefore extends beyond producing test kits.
Nigeria needs laboratories that can use appropriate tests consistently and generate information that health authorities can trust.
Antimicrobial resistance creates another pressure
Antimicrobial resistance is a growing global health concern because microorganisms can become resistant to medicines that previously worked against them.
Laboratory testing is important in determining which organisms are present and which medicines are likely to be effective.
Where laboratories cannot perform adequate microbiological testing, healthcare providers may have less evidence available when selecting treatment.
The 2026 International Journal of Infectious Diseases perspective on diagnostic capacity argued that fragile laboratory systems in many low- and middle-income countries make resistant infections more difficult to detect and weaken surveillance.
For Nigeria, stronger diagnostic capacity could therefore support not only local healthcare but also antimicrobial-resistance surveillance.
That makes investment in laboratories relevant to a wider public-health agenda.
Diagnostics and disease surveillance are connected
Laboratory results can also help establish whether a disease is present in a particular location and whether cases are increasing.
For national health authorities, that information can support decisions about resource allocation and outbreak response.
The more quickly reliable results are generated, the sooner public-health institutions can investigate potential threats.
This is one reason Salako described accurate and timely diagnosis as essential to disease surveillance.
The issue is particularly important in a country as large and geographically diverse as Nigeria.
Disease patterns can vary across regions.
Health facilities also differ significantly in capacity.
A national diagnostic strategy therefore has to consider both central laboratories and the network of laboratories closer to patients.
The workforce is as important as the equipment
Laboratory equipment cannot operate effectively without trained professionals.
Medical laboratory scientists, technicians and other personnel are responsible for specimen handling, testing, quality control, interpretation and reporting.
The Medical Laboratory Science Council of Nigeria regulates training and professional standards for medical laboratory scientists, technicians and assistants.
As diagnostic technologies become more advanced, workforce requirements can also change.
A laboratory may need specialists in molecular diagnostics, bioinformatics, microbiology, pathology, quality management or equipment maintenance.
This means Nigeria's diagnostic strategy needs a workforce-development component.
Training cannot stop at university graduation.
Professionals need continuing education as technologies and standards change.
The MLSCN's digital platform includes continuing professional-development services, reflecting the importance of maintaining professional competence.
Maintenance is an often-overlooked issue
The sustainability of diagnostic systems also depends on equipment maintenance.
A laboratory may receive expensive equipment but eventually lose capacity if the machine breaks down and spare parts or qualified engineers are unavailable.
Maintenance therefore needs to be considered when equipment is purchased.
Local technical capacity can reduce downtime.
Manufacturers and suppliers can also establish service networks.
Universities and technical institutions may contribute to training biomedical engineers and other specialists.
This is another area where technology transfer can have a practical impact.
If domestic manufacturing and servicing capabilities expand together, Nigeria could reduce some of the vulnerabilities associated with external supply chains.
Supply chains remain part of the equation
Even a domestic manufacturer may depend on imported raw materials.
Some specialised components may not currently be produced in Nigeria.
Packaging materials, chemicals, electronic components and specialised equipment can all affect production.
Consequently, local manufacturing does not automatically mean complete independence from international supply chains.
The more realistic objective is resilience.
If Nigeria can produce a greater share of critical products domestically while maintaining multiple external supply options for components that cannot yet be manufactured locally, the health system may become less vulnerable to individual disruptions.
That is different from attempting to eliminate all imports.
Lessons from other health-manufacturing efforts
Nigeria's health sector has already been pursuing local production in other areas.
On September 10, the Federal Ministry of Health and Social Welfare announced the commencement of operations by Health Textiles Nigeria FZE, a facility producing next-generation insecticide-treated mosquito nets.
The ministry described the development as part of efforts to strengthen local production of essential health products.
The facility followed a 2024 memorandum of understanding between Vestergaard and the Presidential Initiative for Unlocking the Healthcare Value Chain.
The mosquito-net project is not a diagnostic manufacturing programme, so it cannot be treated as evidence that Nigeria has solved its laboratory-supply challenges.
However, it illustrates the broader policy direction toward domestic production of health-related products.
The diagnostic sector will face its own technical and regulatory requirements.
The healthcare value-chain approach
The Federal Government's reference to technology transfer, research, regulation, procurement and partnerships reflects a value-chain approach to healthcare manufacturing.
A diagnostic product starts with research and development.
It then moves through design, validation and regulatory approval.
Manufacturing follows.
Distribution must move products to laboratories and healthcare facilities.
Laboratories need trained personnel to use them.
Quality systems need to monitor performance.
Procurement must create sustainable demand.
Data generated from testing feeds into patient care and public-health surveillance.
Weakness in any of these stages can reduce the value of the entire system.
For example, a manufacturer may produce a quality test, but if procurement is unpredictable, the factory may not be financially sustainable.
A laboratory may have modern equipment, but without trained personnel it may not use the equipment correctly.
A hospital may have skilled staff, but if reagents are unavailable, testing can still stop.
This is why the government's latest announcement is framed around an ecosystem rather than a single manufacturing target.
What local production could mean for patients
For patients, the ultimate issue is not industrial statistics.
It is whether reliable diagnostic services become more accessible.
If local manufacturing improves supply stability, hospitals may face fewer shortages of essential products.
If production becomes competitive, prices could potentially become more manageable.
If research and innovation improve, laboratories may gain access to tests better suited to local disease patterns.
If regulatory capacity becomes stronger, patients could benefit from greater confidence in the quality of diagnostic products.
These are potential outcomes rather than guaranteed results.
The September 16 policy announcement establishes direction, but the effect on patients will depend on implementation.
Affordability must remain part of the conversation
Local manufacturing does not automatically mean lower prices.
A Nigerian manufacturer still has to pay for raw materials, electricity, equipment, skilled labour, regulatory compliance, financing, distribution and other operating costs.
If production volumes remain low, unit costs can be high.
That is why sustainable procurement and market development are important.
Manufacturers need enough predictable demand to achieve economies of scale.
Government may also need to create incentives that make investment viable.
At the same time, patients and healthcare providers need products that remain affordable.
The challenge is therefore to develop an industry that is financially sustainable without transferring excessive costs to healthcare users.
Regulation must keep pace with innovation
As diagnostic technologies become more sophisticated, regulators face new questions.
Traditional laboratory products may be evaluated through established procedures.
Digital diagnostics and artificial-intelligence-enabled systems can introduce additional concerns involving algorithms, data quality, validation and cybersecurity.
A 2026 academic study examining AI-enabled diagnostics in Africa identified data sovereignty, infrastructure dependence, regulatory auditability and unequal value capture as issues that policymakers need to consider.
For Nigeria, this suggests that diagnostic sovereignty in the future may involve not only locally manufactured physical products but also control over the technologies and data systems that support diagnosis.
Regulatory institutions will therefore need to adapt as technology evolves.
Artificial intelligence could change the sector
AI is increasingly being incorporated into medical technologies capable of assisting with image analysis, pattern recognition and other diagnostic functions.
Such systems may offer opportunities to extend specialist capacity, particularly where qualified personnel are limited.
But AI also introduces new requirements.
Algorithms have to be validated.
Data used to train systems need to be appropriate.
Performance must be assessed in the populations where the technology will be used.
Regulators need mechanisms for evaluating software as well as physical medical devices.
The academic study of AI-enabled diagnostics in Africa warns that technological adoption without adequate governance can create new forms of dependency even while expanding clinical capability.
Nigeria's emerging diagnostic strategy will therefore have to consider the technological future rather than focusing only on today's laboratory products.
Data governance will become increasingly important
Every diagnostic test generates information.
That information may include patient details, laboratory findings, disease status and other health information.
As laboratories become more digital, questions arise about where data are stored, who can access them and how they are protected.
Diagnostic sovereignty therefore has a data component.
Nigeria's health institutions need systems capable of sharing information where appropriate while protecting patient confidentiality.
Public-health authorities need access to reliable aggregated information.
Researchers may need properly governed datasets.
Patients need confidence that sensitive health information is not being misused.
The development of digital laboratory systems therefore needs to proceed alongside data-protection and cybersecurity measures.
The private sector has a major role
The government alone cannot build a complete diagnostic manufacturing ecosystem.
Private companies will likely provide much of the capital, manufacturing capacity, technical expertise and distribution networks.
The Guild of Medical Laboratory Directors has called for government and stakeholders to create conditions for a competitive local diagnostic industry.
That requires an environment in which qualified companies can invest with reasonable confidence.
Investors need predictable regulation.
Manufacturers need access to financing.
Research companies need pathways to commercialise innovations.
Hospitals need reliable procurement systems.
And patients need products that meet appropriate standards.
Public-private partnerships can potentially connect these interests.
But partnerships also need clear responsibilities and transparent standards.
Universities can help bridge research and manufacturing
Nigeria has universities and research institutions with expertise in medicine, biomedical science, engineering and related disciplines.
One of the challenges is converting research into commercially viable products.
A scientist may develop a promising diagnostic method without having access to manufacturing facilities, regulatory expertise or investment capital.
A manufacturer may have production capacity without access to locally developed technologies.
Connecting these groups can create a stronger innovation pipeline.
Technology-transfer offices, research grants, incubation programmes and partnerships between universities and manufacturers can help bridge the gap.
The government’s inclusion of research and innovation in its diagnostic sovereignty agenda therefore creates room for universities and research institutions to become more directly involved.
The conference's wider message
The 28th Scientific Conference and Annual General Meeting of the Guild of Medical Laboratory Directors is providing a platform for professionals to discuss these issues from the perspective of those working directly within the laboratory system.
The conference discussions have focused not only on manufacturing but also on research, infrastructure, regulation, procurement and professional capacity.
That breadth is important because laboratory medicine sits at the intersection of several parts of healthcare.
A medical laboratory is not simply a room containing machines.
It is a system involving people, specimens, equipment, reagents, quality-control procedures, information systems, regulatory standards and clinical communication.
Strengthening one part without the others may produce limited results.
Nigeria's opportunity is also an industrial challenge
If Nigeria succeeds in developing a competitive diagnostics industry, the impact could extend beyond hospitals.
It could create opportunities for manufacturers, researchers, engineers, logistics providers and skilled professionals.
Local companies could develop products for the Nigerian market and potentially expand into other African countries.
Research institutions could gain incentives to develop applied biomedical technologies.
Technical institutions could train more specialists.
However, none of these outcomes is automatic.
The industry will need investment, standards, predictable demand and effective regulation.
The government's role will be to establish the conditions in which these capabilities can develop.
The risk of replacing import dependence with another dependency
There is also a caution embedded in the concept of diagnostic sovereignty.
If Nigeria imports sophisticated machinery but depends entirely on foreign companies for software, maintenance, spare parts and technical expertise, the country may reduce one form of dependence while retaining others.
The same could happen if local manufacturers assemble imported components without developing domestic technical capability.
That is why technology transfer is part of the government's stated approach.
The objective is not simply to change the label on the final product.
It is to deepen the domestic capability behind the product.
A phased approach may be necessary
Nigeria's diagnostic industry is unlikely to become completely self-sufficient in every category at once.
Some products may be easier to manufacture locally than others.
Basic consumables could potentially have different requirements from highly specialised molecular or genomic technologies.
A phased approach could allow the industry to build capacity progressively.
The government has not announced, in the September 16 statement, a single target covering the percentage of diagnostic products that must be manufactured locally by a particular date.
The immediate policy message is broader: strengthen local production while building the research, regulatory, procurement and partnership systems needed to sustain it.
What will determine whether the policy succeeds
Several practical factors will determine whether the new emphasis produces lasting change.
First is financing.
Diagnostic manufacturing requires capital-intensive equipment and specialised facilities.
Second is electricity and infrastructure.
Manufacturing and laboratory operations depend on reliable power and other utilities.
Third is skilled personnel.
Manufacturers and laboratories need people with technical expertise.
Fourth is regulation.
Products must be assessed efficiently without weakening safety standards.
Fifth is procurement.
Qualified manufacturers need predictable demand.
Sixth is research.
Nigeria needs a pipeline of technologies rather than dependence on imported designs.
Seventh is quality assurance.
Local products must maintain consistent performance.
Eighth is distribution.
Products have to reach facilities across the country rather than remain concentrated in major cities.
These factors are interconnected.
A weakness in one can undermine progress in the others.
What the government has actually announced
It is important to distinguish the current announcement from policies that have not yet been publicly detailed.
The Federal Government has declared diagnostics a strategic national asset.
It has called for stronger local production.
It has identified technology transfer, research and innovation, regulation, sustainable procurement and strategic partnerships as necessary components.
The Guild of Medical Laboratory Directors has called for a competitive domestic industry and highlighted the opportunity presented by the African market.
The regulatory system already assigns the Medical Laboratory Science Council of Nigeria responsibilities for medical laboratory practice, laboratory accreditation and diagnostic reagents and chemicals.
But the September 16 announcement does not by itself establish a complete timetable for replacing imported diagnostic products.
It also does not mean that Nigeria is already self-sufficient in medical diagnostics.
The significance of the development is that the Federal Government is now explicitly framing domestic diagnostic capability as a health-security and industrial priority.
The patient remains the final measure
For all the discussion about manufacturing, technology and industrial policy, the ultimate purpose of diagnostic sovereignty remains patient care.
A diagnostic test matters because it provides information that can help a healthcare professional understand a patient's condition.
If the result is delayed, treatment decisions can be delayed.
If the test is unavailable, clinicians may have less evidence.
If the result is unreliable, the consequences can be serious.
This is why the government has linked diagnostics to accurate and timely healthcare delivery.
The same systems that help an individual patient can also help public-health authorities detect and respond to disease threats.
A new phase for Nigeria's laboratory sector
The Federal Government's declaration on September 16 opens a new phase in Nigeria's discussion about medical laboratory capacity.
The country is being urged to move beyond dependence on imported diagnostic products and build stronger domestic capabilities.
But the proposed transformation is not simply about manufacturing.
It involves the full system supporting diagnosis — research, technology, regulation, professional training, laboratory accreditation, procurement, quality assurance, supply chains, data and patient access.
The Medical Laboratory Science Council's existing regulatory mandate provides one institutional foundation, while the Guild of Medical Laboratory Directors and other professional bodies provide industry and technical perspectives.
The next stage will be determining how these institutions, manufacturers, researchers and government agencies work together.
Nigeria's experience in other areas of healthcare manufacturing shows that local production can become part of a wider strategy for strengthening the health value chain, but diagnostic products bring particularly demanding requirements because their quality directly affects clinical decisions.
The September 16 declaration therefore represents a policy direction rather than the completion of the journey.
The country still has to develop manufacturing capacity, attract investment, strengthen research, train specialists, maintain rigorous regulation and create procurement systems that support qualified producers.
If those elements develop together, Nigeria could reduce some of its exposure to external diagnostic supply disruptions while building a domestic industry capable of serving both Nigerian patients and potentially other African markets.
If they develop separately, the country could end up with isolated factories or modern equipment without the wider ecosystem needed to sustain them.
The Federal Government has now identified the destination: a health system with stronger domestic diagnostic capability and less dependence on imported products.
The more difficult task will be building the infrastructure, expertise, standards and market conditions required to get there.
For patients, the measure of that effort will ultimately be whether reliable diagnostic tests are available when they are needed, whether results can be trusted, and whether healthcare providers can use those results to make informed decisions.
That is what turns diagnostic capacity from an industrial objective into a component of health security.